Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A <i>post-hoc</i> analysis of RELIght study

<b>Background:</b> Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. <b>Objective:</b> In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. <b>Methods:</b> Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. <b>Results:</b> A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. <b>Conclusion:</b> Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov">www.clinical trials.gov</ext-link>.

Authors

Institutions

Publication Details

Journal
Allergy and Asthma Proceedings
Published
2024-12-31
DOI
https://doi.org/10.2500/aap.2025.46.240084
Citations
5
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

Νikolaos Tzanakis, Maria Ntakoula, Andriana Ι. Papaioannou, Κonstantinos Κatsoulis et al.
5 citations
Allergy and Asthma Proceedings
Asthma and respiratory diseases
1.63
article

Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study

Νikolaos Tzanakis, Maria Ntakoula, Andriana Ι. Papaioannou, Κonstantinos Κatsoulis, Maria Kipourou, Evangelia Fouka, Panagiotis Lyberopoulos, Despoina Papakosta, Stylianos Vittorakis, Michael P. Makris, Panteleimon Avarlis, Marija Hadji Mitrova, Anastasia Papaporfyriou, Εleftherios Ζervas, Κonstantinos Porpodis, Katerina Markopoulou, Νikoletta Ρovina, Mina Gaga, Petros Bakakos, Eleni Tzortzaki, Katerina Dimakou, Paschalis Steiropoulos, Stelios Loukides, Sevasti Ampelioti, Katerina M. Antoniou, Κonstantinos Κostikas, Μiltiadis Μarkatos, Sofia Koukidou, Κonstantinos Samitas, Konstantinos Glynos, Maria Kallieri, Εleni Gaki, Ιlias Papanikolaou, Spyros A. Papiris
article en
5 citations

Abstract

<b>Background:</b> Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. <b>Objective:</b> In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. <b>Methods:</b> Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function. <b>Results:</b> A total of 146 patients were evaluated; remission was achieved in 40 (27.4%) and 29 (22%) after 12 and 24 months, respectively. At 12 months, the patients in remission had a better baseline ACT score (17.0 [14.0-19.0] versus 15.0 [12.0-17.0]; p = 0.027), were more rarely using OCS (35% versus 62.2%; p = 0.004), and required a lower baseline dose of OCS (5.0 mg/day [5.0-10.0 mg/day] versus 10.0 mg/day [5.0-15.0 mg/day]; p = 0.042) at baseline, whereas, at 24 months, they less frequently carried a baseline diagnosis of gastroesophageal reflux disease (GERD) (10.3% versus 32%; p = 0.031) and used lower doses of OCS at baseline (5.0 [1.0-5.0] versus 10.0 [5.0-15.0]; p = ≤0.001) versus nonremitters; 52.5% of patients had sustained remission, whereas 42.5% experienced relapse. These patients more frequently had GERD versus patients with sustained remission (52.9% versus 4.8%; p = 0.002). Finally, regression analysis has shown that GERD was the only predictor of relapse. <b>Conclusion:</b> Remitters had better asthma control and needed lower doses or no maintenance OCS at baseline, whereas GERD seems to be an important factor that affects remission and relapse.Clinical trial NCT04084613, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinical trials.gov">www.clinical trials.gov</ext-link>.

Allergy and Asthma ProceedingsVol. 46(1)
University of Crete (GR), Democritus University of Thrace (GR), University of Ioannina (GR), National and Kapodistrian University of Athens (GR), Aristotle University of Thessaloniki (GR), 424 General Military Hospital (GR), Corfu General Clinic (GR), Athens Medical Center (GR), University Hospital of Heraklion (GR), University General Hospital Attikon (GR), G. Papanikolaou General Hospital (GR), e-Trikala (Greece) (GR), Sotiria General Hospital (GR), Medical University of Vienna (AT)
Good health and well-being
Openalex Percentile: Top 15%
Asthma and respiratory diseases
1.63
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.